Protalix BioTherapeutics (NYSE:PLX) Cut to Buy at StockNews.com

StockNews.com downgraded shares of Protalix BioTherapeutics (NYSE:PLX) from a strong-buy rating to a buy rating in a research report released on Tuesday morning.

Separately, HC Wainwright increased their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday.

Protalix BioTherapeutics Stock Up 0.7 %

Shares of NYSE PLX opened at $2.69 on Tuesday. The firm has a 50-day simple moving average of $2.03 and a 200-day simple moving average of $1.44. The stock has a market capitalization of $198.06 million, a price-to-earnings ratio of -20.69 and a beta of 0.75. Protalix BioTherapeutics has a 52 week low of $0.82 and a 52 week high of $2.76.

Institutional Investors Weigh In On Protalix BioTherapeutics

Institutional investors have recently made changes to their positions in the stock. Sanctuary Advisors LLC acquired a new stake in shares of Protalix BioTherapeutics during the third quarter valued at about $38,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Protalix BioTherapeutics during the second quarter valued at about $37,000. Squarepoint Ops LLC increased its position in shares of Protalix BioTherapeutics by 673.3% during the second quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock valued at $161,000 after acquiring an additional 119,949 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of Protalix BioTherapeutics by 8.5% during the third quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock valued at $444,000 after acquiring an additional 33,969 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of Protalix BioTherapeutics during the second quarter valued at about $67,000. 16.53% of the stock is currently owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.